RT Journal Article
SR Electronic
T1 SIGLEC5: An immune checkpoint ligand in sepsis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.30.20117473
DO 10.1101/2020.05.30.20117473
A1 Lozano-Rodríguez, Roberto
A1 Avendaño-Ortíz, José
A1 Montalbán-Hernández, Karla
A1 Ruiz-Rodríguez, Juan Carlos
A1 Ferrer, Ricardo
A1 Martín-Quirós, Alejandro
A1 Maroun-Eid, Charbel
A1 González-López, Juan José
A1 Fàbrega, Anna
A1 Terrón, Verónica
A1 Fresno, Carlos del
A1 Toledano, Víctor
A1 Marín, Elvira
A1 Guitiérrez-Fernández, María
A1 Alonso-López, Elisa
A1 Cubillos-Zapata, Carolina
A1 Stringa, Pablo
A1 Pérez de Diego, Rebeca
A1 Pelegrin, Pablo
A1 García-Palenciano, Carlos
A1 Valentín, Jaime
A1 Gómez-Campelo, Paloma
A1 Aguirre, Luis A.
A1 López-Collazo, Eduardo
YR 2020
UL http://medrxiv.org/content/early/2020/05/30/2020.05.30.20117473.abstract
AB Sepsis is a global health priority. Despite thorough studies in mice models, its molecular and cellular basis remain unclear and there is no pharmacological effective treatment other than antimicrobial and supportive therapy. During sepsis, T cells exhaustion compromises patients’ outcome, and immune checkpoints (ICs) become crucial players in disease management. Here, a total of 425 patients with systemic inflammatory response criteria and 127 controls were studied. Soluble SIGLEC5 (sSIGLEC5) levels in plasma were higher in patients with sepsis compared to the other groups and even higher in those patients with septic-shock. sSIGLEC5 plasma levels were higher in non-survivors than in survivors and ROC curves analysis revealed sSIGLEC5 as a survival marker (cut-off ≤ 523.6 ng/mL). In vitro experiments illustrated how SIGLEC5 impaired CD8+ proliferation through binding to PSGL1. Blocking the SIGLEC5/PSGL1 axis reverted the latter effect. Mechanistically, SIGLEC5 overexpression was driven by HIF1α. Exogenous sSIGLEC5 accelerated death and magnified acute lung injury in mice models. Our data demonstrates how plasma sSIGLEC5 level on admission predicts death and stratifies patients with sepsis. This molecule exhibits the hallmarks of an IC ligand.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from Instituto de Salud Carlos III (ISCIII) and Fondos FEDER to ELC (PIE 15/00065, PI 18/00148, PI 14/01234) and to PP (20859/PI/18) and received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowaska-Curie grant agreement to KMH (No. 713673; La Caixa). CdF was supported by AECC Foundation (INVES192DELF). The Vall d Hebron University Hospital and Vall d Hebron Research Institute were supported by Plan Nacional de I+D+i 2013 to 2016 and Instituto de Salud Carlos III and Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003) cofinanced by European Development Regional Fund A way to achieve Europe, and by the European Union s Horizon 2020 Research and Innovation Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee (La Paz University Hospital, Madrid, PI-3761). Ethics Committee for Animal Experimentation of the Institutional Animal Care and Use Committee at Biomedical Research Institute (IIB, PI-2599).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available.